Plan to implement high-quality active surveillance for favorable-risk prostate cancer
Official title: Planning to implement high-quality active surveillance in new-onset favorable risk prostate cancer
Funded at University of Missouri-Columbia · NIH-11415716 · Data updated 2026-11-12
A health project to improve how men with favorable-risk prostate cancer are monitored instead of treated right away, helping them avoid unnecessary side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | September 13, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2026 |
| Award (this year) | $71,488 |
| NIH project number | 5R34CA283349-03 |
| Project ID | NIH-11415716 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men diagnosed with favorable-risk prostate cancer who are candidates for active surveillance.
✕Less likely to help
Patients with aggressive or non-indolent disease requiring immediate treatment may not benefit from enhanced surveillance strategies.
What this research studies
This grant focuses on ensuring men with favorable-risk prostate cancer are appropriately monitored through active surveillance. It emphasizes confirming indolent disease with timely testing like biopsy or MRI and improving how doctors identify when surveillance is still safe. The work involves understanding how urologists and clinics adopt and implement best-practice surveillance across practices, particularly through the MUSIC network. The goal is to reduce harmful progression by making monitoring more reliable and consistent.
Why it matters
Potential benefit: If successful, patients could experience safer, more consistent monitoring that reduces unnecessary treatments and their side effects.
How similar studies have gone: Prior work shows variable adoption of surveillance practices; this project tests methods to improve implementation.
Where this research is happening
-
University of Missouri-Columbia
Columbia, United States Active
Researchers
- Principal investigator: Sales, Anne Evelyn — University of Missouri-Columbia
- Study coordinator: Sales, Anne Evelyn
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.